M&T Bank Corp Trims Position in Amgen Inc. $AMGN

Key Points

• M&T Bank Corp trimmed its stake in Amgen by 26.2% in Q3, selling 60,616 shares and leaving 170,870 shares valued at about $48.22 million.
• Amgen beat estimates for the quarter with $5.29 EPS vs. $4.76 expected and $9.87B revenue vs. $9.46B, and issued FY2026 guidance of 21.600–23.000 EPS.
• The company declared a quarterly dividend of $2.52 ($10.08 annual, ~2.8% yield, ex-dividend May 15), while analysts' consensus is a Hold with an average price target of $354.

M&T Bank Corp trimmed its position in Amgen Inc. (NASDAQ:AMGN - Free Report) by 26.2% during the 3rd quarter, according to its most recent Form 13F filing with the SEC. The fund owned 170,870 shares of the medical research company's stock after selling 60,616 shares during the period. M&T Bank Corp's holdings in Amgen were worth $48,219,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also recently made changes to their positions in the company. Siemens Fonds Invest GmbH increased its stake in shares of Amgen by 5.8% in the 3rd quarter. Siemens Fonds Invest GmbH now owns 31,509 shares of the medical research company's stock worth $8,892,000 after purchasing an additional 1,735 shares in the last quarter. Diligent Investors LLC increased its position in Amgen by 4.2% in the third quarter. Diligent Investors LLC now owns 1,971 shares of the medical research company's stock worth $556,000 after buying an additional 79 shares in the last quarter. Olde Wealth Management LLC bought a new position in shares of Amgen in the third quarter worth about $306,000. von Borstel & Associates Inc. purchased a new position in shares of Amgen during the 3rd quarter valued at about $258,000. Finally, Bank OZK grew its stake in shares of Amgen by 2.8% during the 3rd quarter. Bank OZK now owns 12,853 shares of the medical research company's stock valued at $3,627,000 after acquiring an additional 351 shares during the period. Hedge funds and other institutional investors own 76.50% of the company's stock.

Wall Street Analysts Forecast Growth

Several equities analysts have weighed in on the stock. Weiss Ratings reaffirmed a "buy (b)" rating on shares of Amgen in a report on Monday, December 29th. Morgan Stanley increased their target price on Amgen from $304.00 to $309.00 and gave the stock an "equal weight" rating in a research report on Wednesday, February 4th. Royal Bank Of Canada boosted their price target on Amgen from $335.00 to $360.00 and gave the stock an "outperform" rating in a report on Wednesday, February 4th. TD Cowen reaffirmed a "buy" rating on shares of Amgen in a report on Wednesday, February 4th. Finally, Barclays initiated coverage on Amgen in a report on Friday, February 20th. They issued an "equal weight" rating and a $350.00 target price on the stock. One analyst has rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating, thirteen have issued a Hold rating and two have assigned a Sell rating to the company's stock. According to MarketBeat.com, the company has an average rating of "Hold" and an average price target of $354.00.

Amgen Stock Down 0.4%

Shares of AMGN opened at $366.21 on Friday. The company has a quick ratio of 0.90, a current ratio of 1.14 and a debt-to-equity ratio of 5.78. The business has a fifty day moving average of $357.73 and a 200 day moving average of $325.17. The company has a market cap of $197.41 billion, a PE ratio of 25.74, a P/E/G ratio of 3.65 and a beta of 0.45. Amgen Inc. has a 52-week low of $261.43 and a 52-week high of $391.29.

Amgen (NASDAQ:AMGN - Get Free Report) last announced its earnings results on Tuesday, February 3rd. The medical research company reported $5.29 earnings per share for the quarter, beating the consensus estimate of $4.76 by $0.53. Amgen had a net margin of 20.98% and a return on equity of 148.37%. The business had revenue of $9.87 billion for the quarter, compared to the consensus estimate of $9.46 billion. During the same quarter in the prior year, the firm posted $5.31 earnings per share. The business's revenue for the quarter was up 8.6% on a year-over-year basis. Amgen has set its FY 2026 guidance at 21.600-23.000 EPS. On average, sell-side analysts expect that Amgen Inc. will post 20.62 EPS for the current year.

Amgen Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Friday, June 5th. Investors of record on Friday, May 15th will be paid a dividend of $2.52 per share. This represents a $10.08 dividend on an annualized basis and a dividend yield of 2.8%. The ex-dividend date of this dividend is Friday, May 15th. Amgen's dividend payout ratio (DPR) is currently 70.84%.

Amgen News Summary

Here are the key news stories impacting Amgen this week:

• Positive Sentiment: Amgen will add medicines to the TrumpRx prescription site, which could expand patient access and volume for listed products if uptake follows; this is a near-term distribution win. GSK and Amgen to add medicines to TrumpRx, Fox Business reports
• Positive Sentiment: Product momentum — coverage highlights MariTide and osteoporosis treatments as sales drivers that have helped fuel recent rallies, supporting revenue growth expectations. Amgen: MariTide And Osteoporosis Sales Fuel The Rally
• Positive Sentiment: Institutional demand: Amgen is a notable holding in income-oriented funds, which supports steady shareholder demand given its long dividend track record. Starbucks, Amgen, and CVS Help This Income Fund Shine
• Positive Sentiment: Operational tie-ins: Rapid Micro Biosystems notes Amgen’s expansion of its Growth Direct system rollout — a small but constructive signal of ongoing manufacturing/capacity investments. Rapid Micro Biosystems Reports Record Fourth Quarter and Full Year 2025 Financial Results and Provides 2026 Guidance
• Neutral Sentiment: Analyst action: Jefferies issued a Hold on AMGN, a neutral rating that can dampen upside momentum vs. more bullish calls. Amgen NASDAQ: AMGN Earns Hold Rating from Analysts at Jefferies Financial Group
• Neutral Sentiment: Press roundups: Amgen appears in broader mega-cap watchlists and industry write-ups — visibility is high but these pieces are more contextual than catalytic. 2 Mega-Cap Stocks to Keep an Eye On and 1 Facing Headwinds
• Negative Sentiment: Dividend/valuation concerns: Independent analysis flags high debt levels, weaker risk-adjusted returns and questions around dividend attractiveness at current prices — these are potential longer‑term headwinds for the stock’s re-rating. Dividend Stock Analysis - Amgen, Inc.

Amgen Profile

Amgen Inc NASDAQ: AMGN is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen's work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen's commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.